Yamanouchi to develop ImaRx agent
Japanese drug firm Yamanouchi Pharmaceutical has begun clinical development in Japan of YM454, the company's version of an ultrasound contrast agent licensed from ImaRx Pharmaceutical of Tucson. Yamanouchi has Asian marketing rights for the agent, which
Japanese drug firm Yamanouchi Pharmaceutical has begun clinical development in Japan of YM454, the company's version of an ultrasound contrast agent licensed from ImaRx Pharmaceutical of Tucson. Yamanouchi has Asian marketing rights for the agent, which ImaRx is co-developing in the U.S. with Du Pont Pharmaceutical under the name DMP115.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
